166 related articles for article (PubMed ID: 19382888)
1. The current status of drug discovery against the human kinome.
Eglen RM; Reisine T
Assay Drug Dev Technol; 2009 Feb; 7(1):22-43. PubMed ID: 19382888
[TBL] [Abstract][Full Text] [Related]
2. Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors.
Eglen RM; Reisine T
Expert Opin Drug Discov; 2010 Mar; 5(3):277-90. PubMed ID: 22823023
[TBL] [Abstract][Full Text] [Related]
3. Drug discovery and the human kinome: recent trends.
Eglen R; Reisine T
Pharmacol Ther; 2011 May; 130(2):144-56. PubMed ID: 21256157
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
5. Fragment-based approaches to the discovery of kinase inhibitors.
Mortenson PN; Berdini V; O'Reilly M
Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
[TBL] [Abstract][Full Text] [Related]
6. The role of structure in kinase-targeted inhibitor design.
Pratt DJ; Endicott JA; Noble ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):428-36. PubMed ID: 15338952
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
8. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
9. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
10. Kinase chemogenomics: targeting the human kinome for target validation and drug discovery.
ter Haar E; Walters WP; Pazhanisamy S; Taslimi P; Pierce AC; Bemis GW; Salituro FG; Harbeson SL
Mini Rev Med Chem; 2004 Mar; 4(3):235-53. PubMed ID: 15032672
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase biochemistry and drug discovery.
Schwartz PA; Murray BW
Bioorg Chem; 2011 Dec; 39(5-6):192-210. PubMed ID: 21872901
[TBL] [Abstract][Full Text] [Related]
12. The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.
Bailey FP; Andreev VI; Eyers PA
Methods Enzymol; 2014; 548():117-46. PubMed ID: 25399644
[TBL] [Abstract][Full Text] [Related]
13. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
Prével C; Kurzawa L; Van TN; Morris MC
Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
[TBL] [Abstract][Full Text] [Related]
14. Doing more than just the structure-structural genomics in kinase drug discovery.
Marsden BD; Knapp S
Curr Opin Chem Biol; 2008 Feb; 12(1):40-5. PubMed ID: 18267130
[TBL] [Abstract][Full Text] [Related]
15. High-throughput structural biology in drug discovery: protein kinases.
Stout TJ; Foster PG; Matthews DJ
Curr Pharm Des; 2004; 10(10):1069-82. PubMed ID: 15078142
[TBL] [Abstract][Full Text] [Related]
16. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.
Dar AC; Shokat KM
Annu Rev Biochem; 2011; 80():769-95. PubMed ID: 21548788
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
Force T; Kuida K; Namchuk M; Parang K; Kyriakis JM
Circulation; 2004 Mar; 109(10):1196-205. PubMed ID: 15023894
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of molecular cancer therapeutics.
van Montfort RL; Workman P
Trends Biotechnol; 2009 May; 27(5):315-28. PubMed ID: 19339067
[TBL] [Abstract][Full Text] [Related]
20. Improved lead-finding for kinase targets using high-throughput docking.
McInnes C
Curr Opin Drug Discov Devel; 2006 May; 9(3):339-47. PubMed ID: 16729730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
